Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

JAK inhibitors and COVID-19.

Levy G. et al, (2022), Journal for immunotherapy of cancer, 10

Human genetic and immunological determinants of critical COVID-19 pneumonia

Zhang Q. et al, (2022), Nature

Degrading JAK2 in ALL by ruxolitinib-based PROTACs

Constantinescu SN. and Pecquet C., (2021), Blood, 138, 2301 - 2302

MPL S505C enhances driver mutations at W515 in essential thrombocythemia.

Varghese LN. et al, (2021), Blood cancer journal, 11

Pituitary incidentaloma.

Constantinescu SM. and Maiter D., (2021), Presse medicale (Paris, France : 1983)

Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.

Mosca M. et al, (2021), Blood

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Bastard P. et al, (2021), Science immunology, 6

CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag.

Basso-Valentina F. et al, (2021), Blood

Functional Consequences of Mutations in Myeloproliferative Neoplasms

Constantinescu SN. et al, (2021), HemaSphere

Targets in MPNs and potential therapeutics

Levy G. et al, (2021), International Review of Cell and Molecular Biology

Include forthcoming?